Neuroprotection in diabetic retinopathy

Current Diabetes Reports

Volumn 12, Issue 4, 2012, Pages 329-337

  Hernández, Cristina ^a   Simó, Rafael ^b  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

Diabetic retinopathy; Docosahexaenoic acid (DHA); Erythropoietin (Epo); Interstitial retinolbinding protein (IRBP); Neurodegeneration; Neuroprotectin 1 (NPD 1); Neuroprotection; Neurovascular coupling; Pathogenesis of diabetic retinopathy; Pigment derived growth factor (PEDF); Somatostatin (SST); Treatment of diabetic retinopathy

Indexed keywords

ADRENOMEDULLIN; BEHENIC ACID; BRAIN DERIVED NEUROTROPHIC FACTOR; BRIMONIDINE; CILIARY NEUROTROPHIC FACTOR; CORTICOSTEROID; DOCOSAHEXAENOIC ACID; ERYTHROPOIETIN; EYE DROPS; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LONG ACTING DRUG; NERVE GROWTH FACTOR; NEUROPROTECTIN D1; OCTREOTIDE; PIGMENT EPITHELIUM DERIVED FACTOR; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR;

CELL MIGRATION; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DIET SUPPLEMENTATION; DISEASE ASSOCIATION; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; ENDOPHTHALMITIS; ENDOTHELIAL PROGENITOR CELL; EXPERIMENTAL ANIMAL; EYE TOXICITY; HUMAN; LASER COAGULATION; MOLECULAR PATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PROTEIN EXPRESSION; RETINA DETACHMENT; REVIEW; TREATMENT PLANNING; VITRECTOMY;

ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; EYE PROTEINS; FEMALE; GLUTAMIC ACID; HUMANS; MALE; MICROCIRCULATION; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM; RETINAL NEURONS; SERPINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84865580448     PISSN: 15344827     EISSN: 15390829     Source Type: Journal    
DOI: 10.1007/s11892-012-0284-5     Document Type: Review

References (93)

1. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-36.
2. Chen E, Looman M, Laouri M, et al. Burden of illness of diabetic macular edema: Literature review. CurrMed Res Opin. 2010;26:1587-97.
3. Lamoureux EL, Wong TY. Diabetic retinopathy in 2011: Further insights from new epidemiological studies and clinical trials. Diabetes Care. 2011;34:1066-7.
4. Javitt JC. Cost savings associated with detection and treatment of diabetic eye disease. Pharmaco Economics. 1995;8 Suppl 1:33-9.
5. Pelletier EM, Shim B, Ben-Joseph R, Caro JJ. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: Results from a US claims data analysis. Pharmaco Economics. 2009;27:479-90.
6. Heintz E, Wiréhn AB, Peebo BB, et al. Prevalence and healthcare costs of diabetic retinopathy: A population-based register study in Sweden. Diabetologia. 2010;53:2147-54.
7. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: A systematic review. 2007; 298:902-16.
8. Simó R, Hernández C. Advances in the medical treatment of diabetic retinopathy. Diabetes Care. 2009;32:1556-62.
9. Simó R, Hernández C. Intravitreous anti-VEGF for diabetic retinopathy: Hopes and fears for a new therapeutic strategy. Diabetologia. 2008;51:1574-80.
10. Joussen AM, Joeres S. Benefits and limitations in vitreoretinal surgery for proliferative diabetic retinopathy and macular edema. Dev Ophthalmol. 2007;39:69-87.
11. Barber AJ, Lieth E, Khin SA, et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest. 1998;102:783-91. (Pubitemid 28399611)
12. Lieth E, Gardner TW, Barber AJ, Antonetti DA, Penn State Retina Research Group. Retinal neurodegeneration: Early pathology in diabetes. Clin Exp Ophthalmol. 2000;28:3-8. (Pubitemid 30433242)
13. Rungger-Brändle E, Dosso AA, Leuenberger PM. Glial reactivity, an early feature of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2000;4:1971-80. (Pubitemid 30354375)
14. Lorenzi M, Gerhardinger C. Early cellular and molecular changes induced by diabetes in the retina. Diabetologia. 2001;44:791-804. (Pubitemid 32642451)
15. Barber AJ. A new view of diabetic retinopathy: A neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:283-90. (Pubitemid 36351495)
16. Asnaghi V, Gerhardinger C, Hoehn T, et al. A role for the polyol pathway in the early neuroretinal apoptosis and glial changes induced by diabetes in the rat. Diabetes. 2003;52:506-11. (Pubitemid 36173210)
17. Antonetti DA, Barber AJ, Bronson SK, et al. JDRF Diabetic Retinopathy Center Group. Diabetic retinopathy: Seeing beyond glucoseinduced microvascular disease. Diabetes. 2006;55:2401-11. (Pubitemid 44871140)
18. Fletcher EL, Phipps JA, Ward MM, et al. Neuronal and glial cell abnormality as predictors of progression of diabetic retinopathy. Curr Pharm Des. 2007;13:2699-712. (Pubitemid 47423662)
19. Barber AJ,Gardner TW,Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011;52:1156-63. In this excellent review the authors give balanced arguments supporting the role of neural and vascular apoptosis in the pathogenesis of DR and define diabetic retinopathy as a form of chronic neurovascular degeneration.
20. Carrasco E, Hernandez C, Miralles A, et al. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care. 2007;30:2902-8. (Pubitemid 350083143)
21. Carrasco E, Hernández C, de Torres I, et al. Lowered cortistatin expression is an early event in the human diabetic retina and is associated with apoptosis and glial activation. Mol Vis. 2008;14:1496-502.
22. Garcia-Ramírez M, Hernández C, Villarroel M et al (2009) Interphotoreceptor retinoid-binding protein (IRBP) is downregulated at early stages of diabetic retinopathy. Diabetologia. 2009; 52:2633-41. This paper demonstrates that underproduction of IRBP is an early event in the human diabetic retina and is associated with retinal neurodegeneration. In addition, a dosedependent downregulation of IRBP mRNA expression and IRBP content was detected with glucose, TNF-alpha and IL-1beta in cultures of Y79 human retinoblastoma cells. Given that IRBP plays a major role in the visual cycle and is essential for the maintenance of photoreceptors, its replacement should be considered a new therapeutic target for DR.
23. Shirao Y, Kawasaki K. Electrical responses from diabetic retina. Prog Retin Eye Res. 1998;17:59-76. (Pubitemid 28040753)
24. Ewing FM, Deary IJ, Strachan MW, Frier BM. Seeing beyond retinopathy in diabetes: Electrophysiological and psychophysical abnormalities and alterations in vision. Endocr Rev. 1998;19:462-76. (Pubitemid 29116016)
25. Bearse jr MA, Adams AJ, Han Y, et al. A multifocal electroretinogram model predicting the development of diabetic retinopathy. Prog Retin Eye Res. 2006;25:425-48. (Pubitemid 44380399)
26. Bronson-Castain KW, Bearse Jr MA, Neuville J, et al. Adolescents with Type 2 diabetes: Early indications of focal retinal neuropathy, retinal thinning, and venular dilation. Retina. 2009;29:618-26.
27. Harrison WW, Bearse MA, Ng J et al. Multifocal electroretinograms predict onset of diabetic retinopathy in adult patients with diabetes. Invest Ophthalmol Vis Sci. 2011;52:772-77. In this paper it is shown that multifocal electroretinogram (mfERG) implicit time (IT) is a good predictor of DR onset. It can be used not only to assess the risk of DR development but also as a valuable outcome measure in the evaluation of novel treatments based on neuroprotection.
28. Ng YK, Zeng XX, Ling EA. Expression of glutamate receptors and calcium-binding proteins in the retina of streptozotocin-induced diabetic rats. Brain Res. 2004;1018:66-72.
29. Pulido JE, Pulido JS, Erie JC, et al. A role for excitatory amino acids in diabetic eye disease. Exp Diabetes Res. 2007;2007:36150.
30. Silva KC, Rosales MA, Biswas SK et al. Diabetic retinal neurodegeneration is associated with mitochondrial oxidative stress and is improved by an angiotensin receptor blocker in a model combining hypertension and diabetes. Diabetes. 2009;58:1382-90. This paper provided first evidence of angiotensin II type I receptor blockade as a neuroprotective treatment of diabetic retinopathy by reestablishing oxidative redox and mitochondrial function.
31. Zong H,Ward M,Madden A et al. Hyperglycemia-induced proinflammatory reponses by retinal Müller glia are regulated by receptor for advanced glycation end-products (RAGE) Diabetologia 2010;53:2656-66. In this paper the authors demonstrated that hyperglycaemia in vivo and in vitro exposure to high glucose induce upregulation of RAGE and its ligands, leading to RAGE signalling, which links to pro-inflammatory responses by retinal Müller glia. These data shed light on the potential clinical application of RAGE blockade to inhibit the progression of diabetic retinopathy.
32. Berner AK, Brouwers O, Pringle R et al. Protection against methylglyoxal-derived AGEs by regulation of glyoxalase 1 prevents retinal neuroglial and vasodegenerative pathology. Diabetologia. 2012;55:845-54. In this paper the authors provide evidence that detoxification of methylglyoxal (an important precursor of AGEs) reduces AGE adduct accumulation, which, in turn, can prevent the formation of key retinal neuroglial and vascular lesions as diabetes progresses.
33. Wilkinson-Berka JL. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol. 2006;38:752-65. (Pubitemid 43372053)
34. Kurihara T, Ozawa Y, Nagai N, et al. Angiotensin II type 1 receptor signaling contributes to synaptophysin degradation and neuronal dysfunction in the diabetic retina. Diabetes. 2008;57:2191-8.
35. Downie LE, Pianta MJ, Vingrys AJ, et al. AT1 receptor inhibition prevents astrocyte degeneration and restores vascular growth in oxigen-induced retinopathy. Glia. 2008;56:1076-90.
36. VillarroelM, Ciudin A, Hernández C, Simó R. Neurodegeneration: An early event of diabetic retinopathy. World J Diabetes. 2010;1:57-64.
37. Shoham S, Bejar C, Kovalev E, et al. Ladostigil prevents gliosis, oxidative-nitrative stress and memory deficits induced by intracerebroventricular injection of streptozotocin in rats. Neuropharmacology. 2007;52:836-43. (Pubitemid 46237641)
38. Cheung AK, Fung MK, Lo AC, et al. Aldose reductase deficiency prevents diabetes-induced blood-retinal barrier breakdown, apoptosis, and glial reactivation in the retina of db/db mice. Diabetes. 2005;54:3119-25. (Pubitemid 43334364)
39. Kusari J, Zhou S, Padillo E, et al. Effect of memantine on neuroretinal function and retinal vascular changes of streptozotocininduced diabetic rats. Invest Ophthalmol Vis Sci. 2007;48:5152-9. (Pubitemid 351260926)
40. Metea MR, Newman EA. Signalling within the neurovascular unit in the mammalian retina. Exp Physiol. 2007;92:635-40. (Pubitemid 47024932)
41. Feng Y,Wang Y, Stock O et al. Vasoregression linked to neuronal damage in the rat with defect of polycystin-2. PLoS One. 2009;4 (10):e7328. In this paper the authors show by using a transgenic rat with overexpression of a mutant cilia gene polycystin-2 the temporal link between neuronal damage and vasoregression.
42. Feng Y, Wang Y, Li L, et al. Gene expression profiling of vasoregression in the retina-involvement of microglial cells. PLoS One. 2011;17(6):e16865.
43. Cervantes-Villagrana AR, García-Román J, González-Espinosa C, Lamas M. Pharmacological inhibition of N-methyl d-aspartate receptor promotes secretion of vascular endothelial growth factor in müller cells: Effects of hyperglycemia and hypoxia. Curr Eye Res. 2010;35:733-41.
44. Kusari J, Zhou SX, Padillo E et al. Inhibition of vitreoretinal VEGF elevation and blood-retinal barrier breakdown in streptozotocin-induced diabetic rats by brimonidine. Invest Ophthalmol Vis Sci. 2010;51:1044-51. In this paper it is demonstrated that brimonidine (an alpha-2 agonist) downregulates VEGF and inhibits the blood-retinal barrier breakdown. This study suggests the role of neurotransmitters in the pathogenesis of DR.
45. Formaz F, Riva CE, Geiser M. Diffuse luminance flicker increases retinal vessel diameter in humans. Curr Eye Res. 1997;16:1252-7. (Pubitemid 27515682)
46. Riva CE, Logean E, Falsini B. Visually evoked hemodynamical response and assessment of neurovascular coupling in the optic nerve and retina. Prog Retin Eye Res. 2005;24:183-215. (Pubitemid 40018224)
47. Nguyen TT, Kawasaki R, Wang JJ, Kreis AJ, Shaw J, Vilser W, Wong TY. Flicker light-induced retinal vasodilation in diabetes and diabetic retinopathy. Diabetes Care. 2009;32:2075-80.
48. Lecleire-Collet A, Audo I, Aout M et al. Evaluation of retinal function and flicker light-induced retinal vascular response in normotensive patients with diabetes without retinopathy. Invest Ophthalmol Vis Sci. 2000;52:2861-7. In this study it is shown that vascular response to flicker light is impaired in patients with diabetes without DR in comparison with controls. These results suggest that, both neural and neurovascular dysfunctions precede the onset of clinically detectable DR.
49. Loomans CJ, van Haperen R, Duijs JM, et al. Differentiation of bone marrow-derived endothelial progenitor cells is shifted into a proinflammatory phenotype by hyperglycemia. MolMed. 2009;15:152-9.
50. Barnstable CJ, Tombran-Tink J. Neuroprotective and antiangiogenic actions of PEDF in the eye: Molecular targets and therapeutic potential. Prog Retin Eye Res. 2004;23:561-77. (Pubitemid 39078362)
51. Shen X, Xie B, Cheng Y, et al. Effect of pigment epithelium derived factor on the expression of glutamine synthetase in early phase of experimental diabetic retinopathy. Ocul Immunol Inflamm. 2011;19:246-54.
52. Cervia D, Casini G, Bagnoli P. Physiology and pathology of somatostatin in the mammalian retina: A current view. Mol Cell Endocrinol. 2008;286:112-22.
53. Simó R, Lecube A, Sararols L, et al. Deficit of somatostatin-like immunoreactivity in the vitreous fluid of diabetic patients: Possible role in the development of proliferative diabetic retinopathy. Diabetes Care. 2002;25:2282-6. (Pubitemid 41071041)
54. Hernández C, Carrasco E, Casamitjana R, et al. Somatostatin molecular variants in the vitreous fluid: A comparative study between diabetic patients with proliferative diabetic retinopathy and nondiabetic control subjects. Diabetes Care. 2005;28:1941-7. (Pubitemid 41060967)
55. Simó R, Carrasco E, García-Ramírez M, Hernández C. Angiogenic and antiangiogenic factors in proliferative diabetic retinopathy. Curr Diabetes Rev. 2006;2:71-98. (Pubitemid 44082952)
56. Lambooij AC, Kuijpers RW, van Lichtenauer-Kaligis EG, et al. Somatostatin receptor 2A expression in choroidal neovascularization secondary to age related macular degeneration. Invest Ophthalmol Vis Sci. 2000;41:2329-35. (Pubitemid 30451010)
57. Kiagiadaki F, Savvaki M, Thermos K. Activation of somatostatin receptor (sst 5) protects the rat retina from AMPA-induced neurotoxicity. Neuropharmacology. 2010;58:297-303.
58. Simó R, Carrasco E, Fonollosa A, et al. Deficit of somatostatin in the vitreous fluid of patients with diabetic macular edema. Diabetes Care. 2007;30:725-7. (Pubitemid 46354362)
59. Hernández C, Simó R. Strategies for blocking angiogenesis in diabetic retinopathy: Fom basic science to clinical practice. Expert Opin Invest Drugs. 2007;16:1209-26. (Pubitemid 47321566)
60. Grant MB, Mames RN, Fitzgeral C, et al. The efficacy of octreotide in the therapy of severe non-proliferative and early proliferative diabetic retinopathy: A randomized controlled study. Diabetes Care. 2000;23:504-9. (Pubitemid 30185795)
61. Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. Octreotide reduces vitreous hemorrhage and loss of visual acuity in patients with high-risk proliferative diabetic retinopathy. Horm Metab Res. 2001;33:300-6. (Pubitemid 32579247)
62. Jansen J, Lamberts S. Circulating IGF-1 and its protective role in the pathogenesis of diabetic angiopathy. Clin Endocrinol. 2000;52:1-9. (Pubitemid 30108277)
63. Wang Q, Dills D, Klein R, Klein B, Moss S. Does insulin-like growth factor predict incidende and progression of diabetic retinopathy? Diabetes. 1995;44:161-4.
64. Growth hormone Antagonist for Proliferative Diabetic Retinopathy. The effect of a growth hormone receptor antagonist drug on proliferative diabetic retinopathy. Ophthalmology 2001;108:2266-2272.
65. Marti HH. Erythropoietin and the hypoxic brain. J Exp Biol. 2004;207:3233-42. (Pubitemid 39275297)
66. Hernández C, Fonollosa A, García-Ramírez M, et al. Erythropoietin is expressed in the human retina and it is highly elevated in the vitreous fluid of patients with diabetic macular edema. Diabetes Care. 2006;29:2028-33. (Pubitemid 44871182)
67. Becerra SP, Amaral J. Erythropoietin: An endogenous retinal survival factor. N Engl J Med. 2002;347:1968-70. (Pubitemid 35429930)
68. Rex TS, Wong Y, Kodali K, Merry S. Neuroprotection of photoreceptors by direct delivery of erythropoietin to the retina of the retinal degeneration slow mouse. Exp Eye Res. 2009;89:735-40.
69. Shen J,Wu Y, Xu JY, et al. ERK-and Akt-dependent neuroprotection by erythropoietin (EPO) against glyoxal-AGEs via modulation of Bcl-xL, Bax, and BAD. Invest Ophthalmol Vis Sci. 2010;5:35-46.
70. García-Ramírez M, Hernández C, Simó R. Expression of erythropoietin and its receptor in the human retina: A comparative study of diabetic and nondiabetic subjects. Diabetes Care 2008;31:1189-1194. This paper demonstrated that Epo overexpression is an early event in the retina of diabetic patients and that this is not associated with any change in EpoR. At this early stage, other factors apart from hypoxia seem to be more important in accounting for the Epo upregulation that exists in the diabetic retina.
71. Katsura Y, Okano T, Matsuno K, et al. Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care. 2005;28:2252-4. (Pubitemid 41242480)
72. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med. 2005;353:782-92. (Pubitemid 41215487)
73. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res. 2002;64:326-33.
74. García-Arumí J, Fonollosa A, Macià C, et al. Vitreous levels of erythropoietin in patients with macular oedema secondary to retinal vein occlusions: A comparative study with diabetic macular oedema. Eye. 2009;23:1066-71.
75. Chen J, Connor KM, Aderman CM, Smith LE. Erythropoietin deficiency decreases vascular stability in mice. J Clin Invest. 2008;118:526-33. (Pubitemid 351206543)
76. Zhang J, Wu Y, Jin Y, et al. Intravitreal injection of erythropoietin protects both retinal vascular and neuronal cells in early diabetes. Invest Ophthalmol Vis Sci. 2008;49:732-42.
77. Wang Q, Gorbey S, Pfister F et al. Long-term treatment with suberythropoietic Epo is vaso-and neuroprotective in experimental diabetic retinopathy. Cell Physiol Biochem 2011;27:769-782. In this manuscript the authors show in streptozotocin-diabetic Wistar rats that neurodegeneration in the diabetic retina was significantly reduced by Epo treatment. In addition, increased VEGF-A levels in the diabetic retina were normalized by Epo treatment.
78. Garcia-Ramírez M, Hernández C, Ruiz-Meana M, et al. Erythropoietin protects retinal pigment epithelial cells against the increase of permeability induced by diabetic conditions: Essential role of JAK2/ PI3K signaling. Cell Signal. 2011;23:1596-602.
79. Grant MB, Boulton ME, Ljubimov AV. Erythropoietin: When liability becomes asset in neurovascular repair. J Clin Invest. 2008;118:467-70. (Pubitemid 351206536)
80. Lagrèze WA, Feltgen N, Bach M, Jehle T. Feasibility of intravitreal erythropoietin injections in humans. Br J Ophthalmol. 2009;93:1667-71.
81. Li W, Sinclair SH, Xu GT. Effects of ontravitreal erythropoietin therapy for patients with chronic and progressive diabetic macular edema. Ophthalmic Surg Lasers Imaging. 2010;41:18-25.
82. Stahl A, Krohne TU, Sapieha P, et al. Lipid metabolites in the pathogenesis and treatment of neovascular eye disease. Br J Ophthalmol. 2011;95:1496-501.
83. SanGiovanni JP, Chew EY. The role of omega-3 long-chain polyunsaturated fatty acids in health and disease of the retina. Prog Retin Eye Res. 2005;24:87-138. (Pubitemid 39535157)
84. Bazan NG. Neurotrophins induce neuroprotective signaling in the retinal pigment epithelial cell by activating the synthesis of the anti-inflammatory and anti-apoptotic neuroprotectin D1. Adv Exp Med Biol. 2008;613:39-44.
85. Mukherjee PK, Marcheselli VL, Serhan CN, Bazan NG. Neuroprotectin D1: A docosahexaenoic acid-derived docosatriene protects human retinal pigment epithelial cells from oxidative stress. Proc Natl Acad Sci U S A. 2004;101:8491-6. (Pubitemid 38736602)
86. Bordet R, Ouk T, Petrault O, et al. PPAR: A new pharmacological target for neuroprotection in stroke and neurodegenerative diseases. Biochem Soc Trans. 2006;34:1341-6. (Pubitemid 46769051)
87. Deplanque D, Gelé P, Pétrault O, et al. Peroxisome proliferatoractivated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment. J Neurosci. 2003;23:6264-71. (Pubitemid 36875628)
88. Bhateja DK, Dhull DK, Gill A, et al. Peroxisome proliferatoractivated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: Possible neuroprotective mechanisms. Eur J Pharmacol. 2012;674:33-43.
89. Dong CJ, Guo Y, Agey P, et al. Alpha 2 adrenergic modulation of NMDA receptor function as a major mechanism of RGC protection in experimental glaucoma and retinal excitotoxicity. Invest Ophthalmol Vis Sci. 2008;49:4515-22.
90. Saylor M, McLoon LK, Harrison AR, Lee MS. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: An evidence-based review. Arch Ophthalmol. 2009;127:402-6.
91. Eljarrat-Binstock E, Pe'er J, Domb AJ. New techniques for drug delivery to the posterior eye segment. Pharm Res. 2010;27:530-43.
92. Lambiase A, Aloe L, Centofanti M, et al. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc Natl Acad Sci USA. 2008;106:13469-74.
93. Aiello LP. Targeting intraocular neovascularization and edema-one drop at a time. N Engl J Med. 2008;359:967-9.